Detection of the Emergence of RAS (Rat Sarcoma Viral Oncogene Homolog) Mutations in Circulating DNA (Deoxyribonucleic Acid) in Patients With mCRC (Metastatic Colorectal Cancer) During Treatment With Anti-EGFR (Epidermal Growth Factor Receptor) Therapy
NCT03908788 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 130
Last updated 2025-04-16
Summary
The analysis of circulating DNA (Deoxyribonucleic acid) to identify potential resistance mechanisms during anti-EGFR (epidermal growth factor receptor) treatment is of great interest, as evidenced by the recent journal published by Corcoran in the prestigious New England Journal of Medicine.
EmutRAS is one of the first studies that will specifically and prospectively evaluate the RAS mutational switch and its impact on the efficiency of the 1st line processing.
Conditions
Interventions
- DEVICE
-
Intplex test
Blood sample at each tumor assessment
Sponsors & Collaborators
-
Institut du Cancer de Montpellier - Val d'Aurelle
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-07-26
- Primary Completion
- 2023-12-03
- Completion
- 2025-10-31
Countries
- France
Study Locations
More Related Trials
-
Comparison of KRAS/BRAF Mutational Status With Conventional Techniques and Plasma Samples Analysis
NCT02784639 ·Status: COMPLETED ·Phase: NA
-
Multicenter Phase 2 Trial: a Tailored Strategy for Locally Advanced Rectal Carcinoma
NCT01333709 ·Status: COMPLETED ·Phase: PHASE2
-
Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer
NCT04117945 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study
NCT05673148 ·Status: RECRUITING ·Phase: PHASE3
-
A Clinical-biological Prospective Cohort of Patients With BRAFV600E-mutated Metastatic Colorectal Cancer
NCT05639413 ·Status: RECRUITING ·Phase: NA
-
EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancer
NCT01008475 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer
NCT06011772 ·Status: ACTIVE_NOT_RECRUITING ·Phase: EARLY_PHASE1
-
A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer
NCT05217446 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Metastatic Left Colon and Rectal Cancer Treatment With Anti_EGFR Targeted Therapy
NCT06083974 ·Status: COMPLETED
-
A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)
NCT02788279 ·Status: COMPLETED ·Phase: PHASE3
-
Celecoxib in Treating Patients With Early-Stage Rectal Cancer
NCT00608595 ·Status: TERMINATED ·Phase: NA
-
Sorafenib in Combination With Irinotecan in Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors
NCT01715441 ·Status: COMPLETED ·Phase: PHASE2
-
Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer
NCT05706779 ·Status: RECRUITING ·Phase: PHASE2
-
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer
NCT04486378 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer
NCT02096354 ·Status: COMPLETED ·Phase: PHASE2
-
Prospective Translational Study Investigating Molecular Predictors of Resistance and Response to Regorafenib Monotherapy
NCT03010722 ·Status: COMPLETED
-
Gene Expression in Patients With Advanced or Metastatic Colorectal Cancer Receiving Bevacizumab
NCT00897754 ·Status: COMPLETED
-
Temsirolimus and Irinotecan for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations
NCT00827684 ·Status: COMPLETED ·Phase: PHASE2
-
Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status
NCT07094893 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
LY3200882 and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer (EORTC1615)
NCT04031872 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Impact of Using the Oncogramme® Device to Select the First Line of Treatment for Patients With Metastatic Colorectal Cancer
NCT05299840 ·Status: RECRUITING ·Phase: NA
-
Prevalence of the Mutational Status of V-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) in Metastatic Colorectal Cancer (mCRC) in Argentine Patients
NCT01082757 ·Status: COMPLETED
-
A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer
NCT05983367 ·Status: TERMINATED ·Phase: PHASE2
-
Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC
NCT04587128 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study of Nimotuzumab and Irinotecan in Metastatic Colorectal Cancer
NCT00493857 ·Status: TERMINATED ·Phase: PHASE2